霍奇金淋巴瘤基线PET扫描中骨髓示踪剂摄取模式的预后价值:一项国际合作研究结果
该回顾性国际研究纳入180例新诊断的早期预后不良和晚期霍奇金淋巴瘤患者,基线及2周期ABVD后行18F-FDG PET扫描。结果显示,局灶性骨髓摄取患者3年无进展生存显著劣于弥漫性和无/ faint摄取患者(66.7%对82.5%,P=0.03),而纯弥漫强摄取与无摄取者无差异(82.9%对82.2%,P=0.918)。结论认为PET是骨髓受累评估的可靠工具,常规分期无需骨髓活检。
要点
- 局灶性骨髓18F-FDG摄取(单灶或多灶)患者3年无进展生存显著低于弥漫性和无/ faint摄取患者(66.7%对82.5%,P=0.03)。
- 纯弥漫强骨髓摄取(>肝脏)与无或 faint(≤肝脏)骨髓摄取患者的3年无进展生存无显著差异(82.9%对82.2%,P=0.918)。
- 骨髓活检阳性率在局灶性摄取组为15.7%(6/38),弥漫性摄取组为1.9%(1/53),无/ faint摄取组为5.6%(5/89)。
核心结论
- 18F-FDG PET扫描是霍奇金淋巴瘤骨髓受累评估的可靠工具,常规分期不再需要骨髓活检。
- 仅局灶性骨髓18F-FDG摄取应被视为霍奇金淋巴瘤的预后不良征兆。
- 骨髓受累评估的观察者间一致性在本研究中表现极好。
研究设计与样本
- 回顾性纳入180例新诊断的早期预后不良和晚期霍奇金淋巴瘤患者,来自2项旨在评估中期PET扫描作用的国际研究。
- 所有患者基线及2周期ABVD后行18F-FDG PET扫描,接受ABVD×4-6周期及必要时受累野放疗,不允许根据中期PET调整治疗。
- 由两名设盲阅片者独立报告扫描结果。
主要发现
- 38例(21.1%)有局灶性骨髓病变(fPET+),其中10例为单灶、28例为多灶。
- 53例(29.4%)为纯强弥漫性骨髓摄取(>肝脏,dPET+),89例(48.4%)无或 faint(≤肝脏)骨髓摄取(nPET+)。
- 骨髓活检阳性:fPET+组6/38(15.7%),dPET+组1/53(1.9%),nPET+组5/89(5.6%)。
- dPET+与较年轻年龄、较高大肿块病变频率、较低血红蛋白水平、较高白细胞计数及脾脏类似弥漫性摄取相关。
- 纯dPET+患者与无任何18F-FDG摄取患者的3年无进展生存相同(82.9%对82.2%,P=0.918)。
关键数值与推荐
- 骨髓受累PET/CT评估中,局灶性骨髓18F-FDG摄取(fPET+)定义为局灶性病变,包括单灶和多灶。
- 纯强弥漫性骨髓摄取(dPET+)定义为摄取>肝脏。
- 无或 faint骨髓摄取(nPET+)定义为摄取≤肝脏。
临床怎么用
- 18F-FDG PET扫描可用于霍奇金淋巴瘤骨髓受累评估,常规分期不再需要骨髓活检。
- 仅局灶性骨髓18F-FDG摄取应被视为霍奇金淋巴瘤的预后不良征兆。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/CT-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analyzed the clinicopathologic correlations and prognostic meaning of different patterns of bone marrow (BM) 18F-FDG uptake in HL. Methods: One hundred eighty newly diagnosed early unfavorable and advanced-stage HL patients, all scanned at baseline and after 2 adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) courses with 18F-FDG PET, enrolled in 2 international studies aimed at assessing the role of interim PET scanning in HL, were retrospectively included. Patients were treated with ABVD × 4-6 cycles and involved-field radiation when needed, and no treatment adaptation on interim PET scanning was allowed. Two masked reviewers independently reported the scans. Results: Thirty-eight patients (21.1%) had focal lesions (fPET+), 10 of them with a single (unifocal) and 28 with multiple (multifocal) BM lesions. Fifty-three patients (29.4%) had pure strong (>liver) diffuse uptake (dPET+) and 89 (48.4%) showed no or faint (≤liver) BM uptake (nPET+). BM biopsy was positive in 6 of 38 patients (15.7%) for fPET+, in 1 of 53 (1.9%) for dPET+, and in 5 of 89 (5.6%) for nPET+ dPET+ was correlated with younger age, higher frequency of bulky disease, lower hemoglobin levels, higher leukocyte counts, and similar diffuse uptake in the spleen. Patients with pure dPET+ had a 3-y progression-free survival identical to patients without any 18F-FDG uptake (82.9% and 82.2%, respectively, P = 0.918). However, patients with fPET+ (either unifocal or multifocal) had a 3-y progression-free survival significantly inferior to patients with dPET+ and nPET+ (66.7% and 82.5%, respectively, P = 0.03). The κ values for interobserver agreement were 0.84 for focal uptake and 0.78 for diffuse uptake. Conclusion: We confirmed that 18F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging. Moreover, the interobserver agreement for BMI in this study proved excellent and only focal 18F-FDG BM uptake should be considered as a harbinger of HL.
引用
- Zwarthoed C, El-Galaly TC, Canepari M, et al. Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. J Nucl Med. 2017. PMID: 28126883. doi:10.2967/jnumed.116.184218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。